Table 10 Participants with ocular Mazzotti reactions starting within 1 Month of treatment by start day and treatment among participants with both eyes evaluated
Mazzotti sign/ symptom | Start after treatment (days) | Moxidectin | Ivermectin | ||||
|---|---|---|---|---|---|---|---|
n | % of N (973) | % of participants with that ocular Mazzotti reaction | n | % of N (490) | % of participants with that ocular Mazzotti reaction | ||
Eye pruritus | 0 | 21 | 2.2 | 46.7 | 3 | 0.6 | 25.0 |
1 | 17 | 1.7 | 37.8 | 6 | 1.2 | 50.0 | |
2 | 2 | 0.2 | 4.4 | 1 | 0.2 | 8.3 | |
3 | 1 | 0.2 | 8.3 | ||||
4 | 1 | 0.1 | 2.2 | ||||
8 | 1 | 0.1 | 2.2 | ||||
11 | 1 | 0.2 | 8.3 | ||||
15 | 1 | 0.1 | 2.2 | ||||
21 | 2 | 0.2 | 4.4 | ||||
Conjunctivitis | 0 | 24 | 2.5 | 58.5 | 3 | 0.6 | 20.0 |
1 | 11 | 1.1 | 26.8 | 4 | 0.8 | 26.7 | |
2 | 3 | 0.3 | 7.3 | 8 | 1.6 | 53.3 | |
3 | 2 | 0.2 | 4.9 | ||||
5 | 1 | 0.1 | 2.4 | ||||
Eye pain | 0 | 8 | 0.8 | 27.6 | 1 | 0.2 | 12.5 |
1 | 14 | 1.4 | 48.3 | 2 | 0.4 | 25.0 | |
2 | 2 | 0.2 | 6.9 | 5 | 1.0 | 62.5 | |
3 | 2 | 0.2 | 6.9 | ||||
4 | 2 | 0.2 | 6.9 | ||||
10 | 1 | 0.1 | 3.5 | ||||
Eyelid oedema | 0 | 8 | 0.8 | 40.0 | |||
1 | 7 | 0.7 | 40.0 | 4 | 0.8 | 80.0 | |
2 | 4 | 0.4 | 40.0 | ||||
3 | 1 | 0.1 | 40.0 | 1 | 0.2 | 20.0 | |
Ocular discomfort | 0 | 7 | 0.7 | 77.8 | 1 | 0.2 | 20.0 |
1 | 1 | 0.1 | 11.1 | 1 | 0.2 | 20.0 | |
3 | 1 | 0.1 | 11.1 | 2 | 0.4 | 40.0 | |
9 | 1 | 0.2 | 20.0 | ||||
Tearing/watery eyes | 0 | 3 | 0.3 | 0.4 | 2 | 0.4 | 28.6 |
1 | 1 | 0.1 | 0.1 | 3 | 0.6 | 42.9 | |
2 | 0.00 | 2 | 0.4 | 28.6 | |||
4 | 1 | 0.1 | 0.1 | ||||
8 | 1 | 0.1 | 0.1 | ||||
11 | 1 | 0.1 | 0.1 | ||||
Blurred vision | 0 | 2 | 0.2 | 66.7 | |||
1 | 3 | 0.6 | 100 | ||||
21 | 1 | 0.1 | 33.3 | ||||
Photophobia | 1 | 1 | 0.2 | ||||
2 | 2 | 0.2 | |||||
Peripheral sensory phenomena | 0 | 1 | 0.1 | 1 | 0.2 | ||
1 | 1 | 0.2 | |||||
Visual acuity | 2 | 1 | 0.1 | ||||